these slides are sufficiently accurate and specific for clinical measurement of urea nitrogen concentrations in blood, as shown in our comparison study (Figure 5) .
Digoxin is a widely-used cardiac glycoside prescribed for control of congestive heart failure and certain cardiac arrhythmias. The clinical value of monitoring digoxin concentrations in the serum of patients being treated with this drug is well established, because the difference between therapeutic and toxic concentrations is small and because total body stores of the drug are difficult to predict (1, 2).
In most clinical laboratories, the technique of choice for determining digoxin in serum is radioirnmunoassay (RIA), because of its sensitivity and specificity. However, RIA has the usual disadvantages associated with isotopic techniques (safety and reagent decay), and in some clinical situations it is not satisfactorily rapid.
In this study we intercompared results obtained with seven RIA kits from different manufacturers and also compared them with an automated fluorescence polarization immunoassay (FPIA) system. When a set of samples is analyzed with various RIA kits, results vary (3), because of differences such as antibody specificity, buffers, separation methods, and incubation conditions. The fluorescence polarization method used in this study is an automated homogeneous assay that requires protein precipitation before analysis. The principles of FPIA have been reviewed (4, 5) and an automated system for FPJA of drug concentrations in human plasma has been described (6). We were initially attracted to the FPIA system because of its speed and simplicity and the stability of its reagents. In our evaluation of the system we used a protocol that allowed us to assess its performance by comparing results by the FPIA with those obtained with several different RIA kits and to view any variation in results by FPIA in terms of the variability among results obtained with the RIA kits.
Materials and Methods
Serum was collected from 33 patients who were being treated with digoxin. The specimens were divided and samples were either assayed the same day or stored at -20 #{176}C until used. Sons, Inc., Princeton, NJ 08540. We generated standard curves by using a log-logit-type curve fit. For FPIA we used the "TDx Analyzer" (Abbott Laboratories) according to the manufacturer's directions. Digoxin determination in the TDx system requires a protein precipitation step before the analysis. To do this, we combined 200 pL of specimen, control, or standard with an equal volume of 50 g/L trichioroacetic acid, centrifuged, and poured the supernates directly into sample cups on the instrument carousel for digoxin determination. Tracer, antibody, and pretreatment reagents were contained in a bar-coded reagent pack, purchased from the instrument manufacturer. Calibrators for the Thx system were USP digoxin in normal human serum at concentrations of 0.5 to 5.0 .tgIL. Digoxin used in analytical recovery studies was from Sigma Chemical Co., St. Louis, MO 63178.
The same samples were used for all eight procedures.
Results were statistically compared by least-squares linearregression analysis and Student's t-test.
Results
Precision. We assayed three concentrations of control material (low, medium, and high) in quadruplicate each day during the course of the study. The results are summarized in Table 1 . All CVs were <7% for the FPIA. The RIA methods showed slightly higher CVs, ranging from 4.1 to 7.5%. Theaverage CV for samples in each concentration range is shown. CVs ranged from 33%at subtherapeutic concentrations to 6.9% in the therapeutic and decision-making levels. the FPJAsystem. The slopes listed are the average (and range) of slopes obtained when the RIA methods were compared. In general, the slopes were close to unity, although method D and the FPIA system tended to give somewhat lower values than the other methods. In three of the seven comparisons, the slopes obtained from the FPIA data were outside (lower than) the range of slopes from the comparisons between RIA methods. Correlation coefficients were 0.96 or greater in all cases. The means for the sample set (n = 36) ranged from 1 (Table 4) . Both RIA methods consistently yielded results >100%; at the lowest concentration of digoxin, both RIA methods showed recoveries of 135%.
Comparison of methods.

Discussion
The RIA technique is used routinely for digoxin determi- Table 3 . Correlation of Methods tion in clinical laboratories. These methods generally rovide clinically reliable results, but intermethod variabiliis substantial. In our study, this was particularly true at low (<0.8 pg/L) concentrations of digoxin. This variability was not consistently related to any methodological differences in the RIA kits we studied. This variability in results by various RIA procedures should be considered when one is monitoring digoxin in patients' samples. The correlation between the FPIA system and the RIA methods was good (r 0.96). In all comparisons but one (kit D), the slopes were <0.92, indicating that the FPIA values tended to be lower than the RIA values. In most of these comparisons, however, the slopes for FPIA vs RIA fell within the range of values obtained when different RIA kits were intercompared. A comparison of the means shows that the FPIA system exhibits a fairly consistent negative bias, which in some cases is statistically significant.
The analytical recovery studies are consistent with our finding that values by FPIA are generally lower than those by RIA for the same specimen. Recovery values obtained by FPIA are considerably closer to the concentrations of added digoxin than were values obtained by the two RIA methods we used for comparison.
The FPIA system provides more rapid analysis (20 mm vs 75 mm), longer shelf-life of reagents (which also require no special licensure for handling), standard curve stability over CLIN. CHEM. 30/7, 1227-1228 (1984) several weeks or longer, better recovery and greater precision than the RIA methods. Among the disadvantages of FPIA are the initial cost of the equipment and higher reagent cost. The latter is offset by the decreased frequency with which the assay must be standardized.
A Commercially Available S-Type Amylase InhibitorEvaluated for Determination of Amylase lsoenzymes in Serum
Norbert W. TIeD 
Materials and Methods
Apparatus. Model 25 spectrophotometer, Beckman Instruments, Inc., Fullerton, CA 92634.
Reagents.
The amylase inhibitor is now commercially available (a-Amylase Inhibitor, Type ifi, cat. no. A-3535; Sigma Chemical Company, St. Louis, MO). The lot used in our experiments was no. 14F8600. This material is not identical to the material previously available from Sigma (a-Amylase Inhibitor, cat. no. A-1520), which we find unsuited for P-type amylase determinations. 
Procedure.
For all experiments we used the manual method as described (1) . Measurement of total amylase activity requires 50 pL of sample-as doesdetermination of P-type amylase, which must be preincubated for 5 mm with 10 L of inhibitor. The precise amount of inhibitor to be added will differ from lot to lot, depending on the purity of the preparation. The amount of inhibitor required for the lot of Sigma inhibitor we used was about 0.67 sg, more than
